Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2006

View Archived Issues

Further preclinical data on TC-2216 presented

Promising results seen with CytoFab in phase II sepsis study

Preclinical antidiabetic efficacy of AS100-244, a novel recombinant globular domain of adiponectin

CeNeS updates M6G status

Alagebrium to be studied in cardiovascular aging

ConjuGon awarded SBIR grant for antibiotic-resistant bacterial infection work

Pharmacopeia and Schering-Plough extend research collaboration

Tocosol Camptothecin studied in phase I solid tumor trial

NOV-205 evaluated for hepatitis C in first U.S. study

Supply agreement for AV-299

Positive pharmacokinetic results for NovaDel's sumatriptan oral spray

Memory achieves milestone in PDE10 collaboration with Amgen

Phase I/II trial investigates eniluracil and 5-FU for hepatocellular cancer

Affinium Pharmaceuticals profiles new anti-staphylococcal agent, API-1252

European orphan drug designation recommended for Cytotect

TAP and Novartis to copromote Famvir in U.S.

Novel chloride CIC-7 channel inhibitor PB-5430 reduces bone resorption in OVX rats

Novel GSK-3 inhibitor increases trabecular bone mass in mice

Merck & Co. revises filing plans for MK-0524B

More negative phase III outcomes for Corlux in psychotic major depression

R&D highlights from the UBS Global Life Sciences Conference in New York: Ziopharm Oncology

PF-00422602: Pfizer's novel oxazolidinone active against Gram-positive bacteria

Approvable letter for cryopreserved OrCel in epidermolysis bullosa

Toll-like receptor agonist 3M-003 shows antifungal activity in vitro

Pylera receives approval letter for eradication of H. pylori

NDA submission for EvaMist

Arixtra ACS filing accepted for priority review

European approval for Synvisc in ankle and shoulder osteoarthritis indications

Natural extract from Chinese herb shows benefit in rheumatoid arthritis

E.U. filing for febuxostat in symptomatic hyperuricemia accepted for review

Novel agents for sleep disorders, schizophrenia, etc. claimed in recent patents

Novel therapeutic agents for infectious diseases disclosed in recent patent literature

New therapeutic strategies for cancer imparted in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...